Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiethop, B. V.
Right arrow Articles by Cryer, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiethop, B. V.
Right arrow Articles by Cryer, P. E.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 16, Issue 8 1131-1136, Copyright © 1993 by American Diabetes Association


ARTICLES

Alanine and terbutaline in treatment of hypoglycemia in IDDM

BV Wiethop and PE Cryer
Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.

OBJECTIVE--To test the hypothesis that, in contrast to administration of glucose or glucagon, administration of the amino acid Ala or of the beta 2-adrenergic agonist terbutaline produces sustained glucose recovery from hypoglycemia. RESEARCH DESIGN AND METHODS--We developed a model of clinical hypoglycemia using subcutaneous injection of insulin (0.15 U/kg) in patients with IDDM. In comparison with nondiabetic subjects, patients with IDDM exhibited reduced glucagon (P = 0.0001), epinephrine (P = 0.0060), and pancreatic polypeptide (P = 0.0001) responses to hypoglycemia. In addition to placebos, the following were administered during hypoglycemia (2 h after insulin injection) in IDDM patients: oral glucose, 10 and 20 g; subcutaneous glucagon, 1.0 mg; oral Ala, 40 g; oral terbutaline, 5.0 mg; and subcutaneous terbutaline, 0.25 mg. RESULTS--Glucose (10 and 20 g) and glucagon raised plasma glucose (P = 0.0163, 0.0060, and 0.0001, respectively) from 3.0-3.3 mM to peaks of 5.4 +/- 0.4, 6.8 +/- 0.7, and 11.8 +/- 0.8 mM within 30, 45, and 60 min, respectively, but the responses were transient. Oral Ala raised glucose levels (P = 0.0401) to 4.0 +/- 0.4 mM within 30 min; glucose levels then rose gradually to a 6-h value of only 7.1 +/- 0.9 mM. Oral terbutaline raised glucose levels (P = 0.0294) to 4.3 +/- 0.3 mM within 30 min; glucose levels then rose substantially. In contrast, subcutaneous terbutaline raised glucose levels (P = 0.0249) to 3.7 +/- 0.1 mM within 15 min; the levels plateaued at 5.0 mM from approximately 60-150 min and then paralleled the placebo curve. CONCLUSIONS--Ala and terbutaline produce sustained glucose recovery from hypoglycemia in IDDM and are therefore potentially useful agents for the treatment of mild or moderate iatrogenic hypoglycemia, or the prevention of iatrogenic hypoglycemia, when food intake is not anticipated over the following several hours.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
P. Rossetti, F. Porcellati, N. Busciantella Ricci, P. Candeloro, P. Cioli, K. S. Nair, F. Santeusanio, G. B. Bolli, and C. G. Fanelli
Effect of Oral Amino Acids on Counterregulatory Responses and Cognitive Function During Insulin-Induced Hypoglycemia in Nondiabetic and Type 1 Diabetic People
Diabetes, July 1, 2008; 57(7): 1905 - 1917.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. E. De Galan, P. De Mol, L. Wennekes, B. J. J. Schouwenberg, and P. Smits
Preserved Sensitivity to {beta}2-Adrenergic Receptor Agonists in Patients with Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2878 - 2881.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Raju, A. M. Arbelaez, S. M. Breckenridge, and P. E. Cryer
Nocturnal Hypoglycemia in Type 1 Diabetes: An Assessment of Preventive Bedtime Treatments
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2087 - 2092.
[Abstract] [Full Text] [PDF]


Home page
The Diabetes EducatorHome page
J. Y. Venters, A. E. Hunt, J. F. Pope, and E. F. Molaison
Are Patients With Diabetes Receiving the Same Message From Dietitians and Nurses?
The Diabetes Educator, March 1, 2004; 30(2): 293 - 300.
[PDF]


Home page
Diabetes CareHome page
P. E. Cryer, S. N. Davis, and H. Shamoon
Hypoglycemia in Diabetes
Diabetes Care, June 1, 2003; 26(6): 1902 - 1912.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child.Home page
N P Wright and J K H Wales
The incidence of hypoglycaemia in children with type 1 diabetes and treated asthma
Arch. Dis. Child., February 1, 2003; 88(2): 155 - 156.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
O. Chan, S. Chan, K. Inouye, K. Shum, S. G. Matthews, and M. Vranic
Diabetes Impairs Hypothalamo-Pituitary-Adrenal (HPA) Responses to Hypoglycemia, and Insulin Treatment Normalizes HPA but not Epinephrine Responses
Diabetes, June 1, 2002; 51(6): 1681 - 1689.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. J. Franz, J. P. Bantle, C. A. Beebe, J. D. Brunzell, J.-L. Chiasson, A. Garg, L. A. Holzmeister, B. Hoogwerf, E. Mayer-Davis, A. D. Mooradian, et al.
Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications
Diabetes Care, January 1, 2002; 25(1): 148 - 198.
[Full Text] [PDF]


Home page
Diabetes Spectr.Home page
P. E. Cryer and B. P. Childs
Negotiating the Barrier of Hypoglycemia in Diabetes
Diabetes Spectr, January 1, 2002; 15(1): 20 - 27.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
E. Cersosimo, P. Garlick, and J. Ferretti
Abnormal Glucose Handling by the Kidney in Response to Hypoglycemia in Type 1 Diabetes
Diabetes, September 1, 2001; 50(9): 2087 - 2093.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1993 by the American Diabetes Association.